


**UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE QUARTER ENDED 31st DECEMBER, 2013**

Part - I		. (Rs. In Millions)					
S. No.	PARTICULARS	Quarter Ended on			Nine Months Ended on		Year Ended on
		31/12/2013 Unaudited	30/09/2013 Unaudited	31/12/2012 Unaudited	31/12/2013	31/12/2012	31/03/2013 Audited
1	Net Sales/ Income from operations						
	Gross Sales	1304.58	1246.96	1119.09	3820.33	3349.47	4,602.58
	Less : Excise Duty	2.35	1.68	2.85	6.37	8.78	11.61
	(a) Net Sales	1302.23	1245.28	1116.24	3813.96	3340.69	4,590.97
	(b) Other Operating Income	10.38	7.15	10.12	23.16	19.52	22.41
	Total Income from Operation (Net)	1,312.61	1,252.43	1,126.36	3,837.12	3,360.21	4,613.38
2	Expenses						
	(a) Consumption of raw materials	702.41	704.12	635.35	2159.03	1,939.90	2,725.58
	(b) (Increase)/ Decrease in stock in trade	(7.53)	22.51	0.55	12.18	(61.1)	(92.93)
	(c) Employee benefits expense	59.95	59.66	58.35	178.78	173.51	232.38
	(d) Depreciation & amortisation expense	97.17	96.87	80.09	289.39	237.55	317.62
	(e) Other expenses	199.73	142.15	133.09	489.02	423.79	563.47
	Total expense	1,051.73	1,025.31	907.43	3,128.40	2,713.65	3,746.12
3	Profit from operations before other income , finance costs and exceptional items (1-2)	260.88	227.12	218.93	708.72	646.56	867.26
4	Other income	0.71	0.21	3.45	2.14	7.40	3.95
5	Profit before finance costs and exceptional items (3+4)	261.59	227.33	222.38	710.86	653.96	871.21
6	Finance Costs	83.43	69.21	52.94	219.45	182.81	244.49
7	Profit after finance costs but before exceptional items (6-5)	178.16	158.12	169.44	491.41	471.15	626.72
8	Exceptional items	0.00	0.00	00.00	0	00.00	00.00
9	Profit from ordinary activities before tax (7+8)	178.16	158.12	169.44	491.41	471.15	626.72
10	Tax expense	5.88	8.15	08.89	23.00	19.23	55.27
11	Profit from ordinary activities after tax (9-10)	172.28	149.97	160.55	468.41	451.92	571.45
12	Exceptional items (net of tax expense	00.00	00.00	00.00	0.00	0.00	0.00
13	Net profit for the period (11-12)	172.28	149.97	160.55	468.41	451.92	571.45
14	Paid up Equity Share Capital	114.42	114.42	97.42	114.42	97.42	105.42
15	Reserves excluding revaluation reserves	N. A.	N. A.	N. A.	N. A.	N. A.	3,769.22
16	E.P.S - Basic not annualised for the qtr	15.06	13.11	16.48	40.94	46.39	54.21
	- Annualised	60.23	52.43	65.92	81.88	61.85	54.21
	Part - II						
1	Public Shareholding						
	- Number of Shares	6437086	6437086	6437086	6437086	6437086	6437086
	- Percentage of Shareholding	56.26	56.26	66.08	56.26	66.08	61.06
2	Promoters and promoter group shareholding						
a)	Pledged as collateral security to bank						
	- Number of Shares	1930000	1930000	1430000	1930000	1430000	1930000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	38.56	38.56	43.27	38.56	43.27	47.02
	- Percentage of shares (as a % of the total share capital	16.87	16.87	14.67	16.87	14.67	18.31
b)	Non-Encumbered						
	- Number of Shares	3074902	3074902	1874902	3074902	1874902	2174902
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	61.44	61.44	56.73	61.44	56.73	52.98
	- Percentage of shares (as a % of the total share capital	26.87	26.87	19.25	26.87	19.25	20.63
	Particulars	3 months ended 31.12.2013					
	(B) INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	NIL					
	Received during the quarter	0					
	Disposed of during the quarter	0					
	Remaining unresolved at the end of the quarter	NIL					

For **VENUS REMEDIES LIMITED**

CHAIRMAN & MANAGING DIRECTOR

Notes:

1. The above Un-audited (Provisional) financial Results for the period ended 31.12.2013 were reviewed by the Audit Committee and taken on record at the board Meeting on February 12, 2014.
2. During the Quarter:
 - a) The Company has made inroad into Latin America with its patent protected novel antibiotic adjuvant entity Elores.
 - b) The Company received market authorization for its generic broad spectrum antibiotic injectable Meropenem.
 - c) Venus becomes first pharma firm to get marketing approval for meropenem in Gulf
 - d) Venus bags UBM India Pharma Award for Elores
 - e) Venus Remedies signs MoU for Elores with South African pharmaceutical firm
 - f) Venus wins "Innovative 100" Award for ELORES .
 - g) Venus Medicine Research Centre signed MoU with Baba Farid university to undertake collaborative research projects and academic programmes.
3. The Statutory Auditors have carried out Limited Review of the above Un- audited financial results in terms of Clause 41 of the listing Agreement.
4. During the Quarter, no investor grievance was received. No other investor grievance was pending at the end of the quarter.
5. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED

Place : Panchkula
Date : 12.02.2014


(Pawan Chaudhary)
Chairman & Managing Director

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : 1 91-1795-302100, 302101, 302107, Fax : 1 91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany



J. K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1132-33, Sector 22-B, CHANDIGARH - 160 022

0172-270 4536-37 Fax : 0172-270 4537

E-mail : jkjcaps@rediffmail.com

REVIEW REPORT


The Board of Directors,
Venus Remedies Limited
51-52, Industrial Area, Phase-I
Panchkula

We have reviewed the accompanying statement of un-audited Financial Results of **Venus Remedies Limited** for the Nine months/Quarter ended 31.12.2013. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, 'Engagements to Review financial statements' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited Quarterly financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for J. K. Jain & Associates,
Chartered Accountants


(J.K. Jain)

Partner

M.No. 083140

FRN. 004025N

Date : 12.02.2014
Place : Chandigarh